Coronavirus / COVID

Evaluating the impact of the SARS-CoV-2 virus on hospitalized patients.

In an effort to understand the potential burden of asymptomatic SARS-Cov-2 infections in a traveling population, a group of investigators studied those entering China.

In this era of increasingly mobile and connected populations, it is possible for an infection to spread around the world in 24 to 48 hours.

The World Health Organization (WHO) listed the vaccine for emergency use to enable countries who do not have vaccine agreements in place to work towards vaccinating their populations.

Preprint data show a US-based variant has come to represent more than 27% and 11% of all sequenced genomes in Louisiana and New Mexico, respectively, through mid-January.

CalciMedica has developed Auxora, a calcium release-activated calcium (CRAC) channel inhibitor, and it has shown it can reduce the levels of D-dimer, a key biomarker associated with COVID-19 mortality.

Case numbers trend downward in Germany as UK implements new border policies.

A new study suggests nursing homes with more people of color are actually at three-fold greater risk of COVID-19 mortality.

New South Africa-based data show not only lessened protection versus the region's dominant variant, but a reduced vaccine-induced antibody neutralization.

Detailed analysis of SARS-CoV-2 showed predominant infection of human lung epithelial cells.

The study used electronic health record data and took account of a range of potentially influential factors.

Vaccination potential will not be achieved without a successful rollout plan.

CDC director says this is not mandatory, but is a road map and provides strategies for schools to reopen safely.

Decision comes as Biden states all Americans won’t be vaccinated by the end of summer.

Do people of varying age groups look at wearing a face mask differently?

Proper assessment of the severity and extent of pulmonary involvement is of paramount importance.

Evidence shows demographic structure and age-specific contacts play an essential role in the epidemic.

Patients with severe COVID-19 experienced positive benefits reducing mortality and intubation rates when using the therapy along with Decadron and convalescent plasma.

Quality face masks remain an important part of our fight against the virus, as most people are still unvaccinated. New virus variants may mean extended mask wearing.

The country announced it is going to study the use of the Johnson & Johnson vaccine for health care workers and will not go forward with plans to use the AstraZeneca vaccine.

The Centers for Disease Control and Prevention (CDC) weighs in on this topic in light of the new variants.

The EUA follows the authorization for lone therapy bamlanivimab for adults and children at risk of severe COVID-19.

The UK announced it is beginning a 2-dose study using one dose of the Pfizer/BioNTech and one dose of AstraZeneca in each individual participant.

In most areas tested, the algorithm's estimates of infections corresponded to the percentage of people who had tested positive for antibodies.